Therapeutic targeting of immunometabolism in Alzheimer's disease reveals a critical reliance on Hexokinase 2 dosage on microglial activation and disease progression. - Codocedo JF; Mera-Reina C; Lin PB; Puntambekar SS; Casali BT; Jury N; Martinez P; Lasagna-Reeves CA; Landreth GE (BioRxiv : the preprint server for biology, 2023)